Evidence map›Paper›PMID 41792452›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Icaritin ameliorates MPTP-induced Parkinson's disease model by targeting the NLRP3 inflammasome pathway.

Chengnian Yang, Yuanyuan Li, Tingting Liu, Rui Liang, Juan Huang, Yong Luo, Nanqu Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chengnian Yang *Department of Pathology, Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China.
Yuanyuan Li *National Drug Clinical Trial Institution, Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China.
Tingting LiuNational Drug Clinical Trial Institution, Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China.
Rui LiangDepartment of Pathology, Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China.
Juan HuangKey Laboratory of Basic Pharmacology and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Yong LuoDepartment of Geriatrics, Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China. luoyong@zmu.edu.cn.
Nanqu HuangNational Drug Clinical Trial Institution, Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China. hnq@zmu.edu.cn.

Funding

Guizhou Provincial Science and Technology Department ZK[2023]-4904, Thousand Talents ProgramNational Natural Science Foundation of China 82260774Zunyi Science and Technology Bureau 2022-50
6 · The paper itself

Abstract

Neuroinflammation, particularly through the NLRP3 inflammasome, plays a significant role in the progression of Parkinson's disease (PD). Icaritin (ICT), a flavonoid compound derived from Epimedium, has demonstrated potential therapeutic effects on PD. In this study, an MPTP-induced PD mouse model was used to evaluate the impact of ICT. The mice were treated with ICT through intragastric administration, and their motor functions were assessed by the rotarod test and the pole test. Immunofluorescence was used to examine the expression of TH, Iba1, and GFAP, and Western blotting was used to measure changes in the levels of NLRP3 and other relevant proteins. The results showed that ICT significantly improved motor dysfunction induced by MPTP, reduced dopaminergic neuronal damage, diminished glial cell activation, and inhibited the expression of proteins in the NLRP3 signalling pathway. These findings suggest that ICT has a protective effect on the MPTP-induced PD mouse model and that its mechanism of action is likely related to the inhibition of NLRP3-mediated neuroinflammation.

Indexed as

FlavonoidsInflammasomesMPTP PoisoningNeuroprotective AgentsNLR Family, Pyrin Domain-Containing 3 ProteinParkinsonian DisordersAnimalsDisease Models, AnimalDopaminergic NeuronsMaleMiceMice, Inbred C57BLMotor ActivitySignal TransductionFlavonoidsicaritinInflammasomesNeuroprotective AgentsNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseGlial cellsIcaritinInflammasomeNeuroinflammationNLR family pyrin domain-containing 3Parkinson's disease

Identifiers

PMID41792452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.